YC
ALNY icon

Yarbrough Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Yarbrough Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,376
Closed -$372K – 156
2025
Q1 		$372K Hold
1,376
– – 0.02% 153
2024
Q4 		$324K Hold
1,376
– – 0.01% 165
2024
Q3 		$378K Buy
+1,376
New +$358K 0.02% 163

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Yarbrough Capital's ALNY Position: Q2 2025 in Review

Yarbrough Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 1,376 shares — an estimated $372K sold.

Yarbrough Capital first reported a position in ALNY in Q3 2024 and held it in 3 quarters. The position peaked at $378K in Q3 2024. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Yarbrough Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Yarbrough Capital sold 1,376 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $372K.
  • Yarbrough Capital first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Yarbrough Capital's Alnylam Pharmaceuticals position peaked at $378K in Q3 2024.
  • 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Yarbrough Capital's 13F filing for Q2 2025, filed 15 Jul 2025.